Financials data is unavailable for this security.
View more
Year on year Tsumura & Co had little change in net income (from 16.48bn to 16.71bn) despite revenues that grew 7.71% from 140.04bn to 150.85bn. A contributing factor has been an increase in the cost of goods sold as a percent of sales from 51.24% to 54.38%.
| Gross margin | 48.76% |
|---|---|
| Net profit margin | 16.48% |
| Operating margin | 18.61% |
| Return on assets | 6.23% |
|---|---|
| Return on equity | 9.02% |
| Return on investment | 7.63% |
More ▼
Cash flow in JPYView more
In 2024, cash reserves at Tsumura & Co fell by 16.70bn. However, the company earned 5.61bn from its operations for a Cash Flow Margin of 3.72%. In addition the company used 19.35bn on investing activities and also paid 4.42bn in financing cash flows.
| Cash flow per share | 504.47 |
|---|---|
| Price/Cash flow per share | 9.73 |
| Book value per share | 3,875.47 |
|---|---|
| Tangible book value per share | 3,635.65 |
More ▼
Balance sheet in JPYView more
| Current ratio | 5.40 |
|---|---|
| Quick ratio | 3.04 |
| Total debt/total equity | 0.2425 |
|---|---|
| Total debt/total capital | 0.1806 |
More ▼
Growth rates in JPY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 32.81% and 1.95%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 2.08% |
|---|---|
| Div growth rate (5 year) | 5.84% |
| Payout ratio (TTM) | 35.82% |
| EPS growth(5 years) | 2.87 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 85.94 |
More ▼
